Pulmonary Solid and Granular Adenocarcinomas Expressing HepPar1: Highly Aggressive Tumors Exhibiting Mitochondrial Adaptation to STK11 Mutations rather than Hepatoid Differentiation.
Academic Article
Overview
abstract
Hepatoid lung carcinomas, similar to hepatoid carcinomas of other sites, are defined as extrahepatic tumors exhibiting divergent hepatocellular differentiation. Uniquely, hepatoid carcinomas of lung origin are reported to commonly express only HepPar1 - a hepatocellular marker, which recognizes mitochondrial enzyme carbamoyl-phosphate synthetase-1 (CPS1). Recently, HepPar1/CPS1 was found to accumulate in lung adenocarcinomas (LUAD) harboring STK11 mutations, presumably as a genotype-associated metabolic adaptation. The impact of these insights on the concept of hepatoid lung carcinoma has not been explored. Here, we performed a detailed clinicopathologic and genomic analysis on carcinomas prospectively regarded as hepatoid with isolated HepPar1 expression (n=17). We found that while robustly positive for HepPar1, these tumors were entirely negative for an extended panel of other hepatocellular markers (AFP, Arginase1, Glypican3, Albumin-ISH). Morphologically, tumors exhibited solid-trabecular architecture with expanded granular-vacuolated-clear cytoplasm, thus evoking hepatoid morphology; however, focal-to-moderate intracytoplasmic mucin was consistently present and hepatoid resemblance was variable. Pneumocytic markers (TTF1, Napsin A) were entirely negative (except for cytoplasmic TTF1), commonly leading to diagnostic challenges at metastatic sites. Remarkably, next-generation sequencing revealed invariable STK11 mutations/loss (P<0.00001 vs unselected LUAD, n>2.5K). Patient survival was dismal (median: 5.8 vs 25 months for stage-matched LUAD, P=0.0002). Tumors harbored high mitochondrial content by electron microscopy and other methods. For comparison, we reviewed conventional, predominantly acinar LUAD with HepPar1 expression (n=22), and found that they also lacked any other hepatocellular markers, had invariable STK11 mutations/loss, increased granular cytoplasm, lower TTF1 and poor prognosis. We conclude that isolated HepPar1 expression in LUAD reflects mitochondrial adaptation to STK11 mutations rather than bona fide hepatocellular differentiation, and that HepPar1-expressing solid and granular adenocarcinomas (SAGA) represent an undifferentiated (solid, TTF1-negative) variant in this spectrum of tumors. Recognition of these tumors is warranted due to their exceptionally aggressive behavior, distinct pathogenomic features and common association with diagnostic challenges.
